UA120450C2 - Сполуки і похідні сульфонімідоїлпуринону для лікування і профілактики вірусної інфекції - Google Patents

Сполуки і похідні сульфонімідоїлпуринону для лікування і профілактики вірусної інфекції Download PDF

Info

Publication number
UA120450C2
UA120450C2 UAA201712023A UAA201712023A UA120450C2 UA 120450 C2 UA120450 C2 UA 120450C2 UA A201712023 A UAA201712023 A UA A201712023A UA A201712023 A UAA201712023 A UA A201712023A UA 120450 C2 UA120450 C2 UA 120450C2
Authority
UA
Ukraine
Prior art keywords
purin
methyl
amino
compound
alkyl
Prior art date
Application number
UAA201712023A
Other languages
English (en)
Ukrainian (uk)
Inventor
Чуньгень Лян
Кунь Мяо
Цзяньпін Ван
Цзяньпин ВАН
Хунін Юнь
Хунин ЮНЬ
Сюфан Чжен
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55910966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA120450(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of UA120450C2 publication Critical patent/UA120450C2/uk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
UAA201712023A 2015-05-08 2016-05-04 Сполуки і похідні сульфонімідоїлпуринону для лікування і профілактики вірусної інфекції UA120450C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2015078507 2015-05-08
CN2016078785 2016-04-08
PCT/EP2016/059961 WO2016180695A1 (en) 2015-05-08 2016-05-04 Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection

Publications (1)

Publication Number Publication Date
UA120450C2 true UA120450C2 (uk) 2019-12-10

Family

ID=55910966

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201712023A UA120450C2 (uk) 2015-05-08 2016-05-04 Сполуки і похідні сульфонімідоїлпуринону для лікування і профілактики вірусної інфекції

Country Status (32)

Country Link
US (3) US9708325B2 (https=)
EP (1) EP3294740B1 (https=)
JP (1) JP6738352B2 (https=)
KR (1) KR102690131B1 (https=)
CN (1) CN107580596B (https=)
AR (1) AR104528A1 (https=)
AU (3) AU2016260683B2 (https=)
BR (1) BR112017023959B1 (https=)
CA (1) CA2982704C (https=)
CL (1) CL2017002745A1 (https=)
CO (1) CO2017009994A2 (https=)
CR (1) CR20170496A (https=)
DK (1) DK3294740T3 (https=)
ES (1) ES2753777T3 (https=)
HR (1) HRP20191942T1 (https=)
HU (1) HUE045906T2 (https=)
IL (2) IL254947B (https=)
LT (1) LT3294740T (https=)
MX (2) MX376761B (https=)
MY (1) MY182353A (https=)
NZ (2) NZ775222A (https=)
PE (1) PE20171620A1 (https=)
PH (1) PH12017502009A1 (https=)
PL (1) PL3294740T3 (https=)
PT (1) PT3294740T (https=)
RS (1) RS59435B1 (https=)
RU (1) RU2745269C2 (https=)
SG (1) SG10202108841YA (https=)
SI (1) SI3294740T1 (https=)
TW (2) TWI706954B (https=)
UA (1) UA120450C2 (https=)
WO (1) WO2016180695A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3294740T3 (pl) * 2015-05-08 2020-03-31 F. Hoffmann-La Roche Ag Nowe sulfonoimidoilopurynony i pochodne do leczenia i profilaktyki infekcji wirusowych
AU2017320742B2 (en) 2016-08-29 2021-08-05 F. Hoffmann-La Roche Ag 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
CN109715214B (zh) 2016-09-13 2022-03-04 豪夫迈·罗氏有限公司 Tlr7激动剂和hbv衣壳组装抑制剂的组合治疗
JP7328977B2 (ja) 2018-02-12 2023-08-17 エフ. ホフマン-ラ ロシュ アーゲー ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体
RU2020131012A (ru) * 2018-02-28 2022-03-28 Ф. Хоффманн-Ля Рош Аг 7-замещенные соединения сульфонимидоилпуринонов и их производные для лечения и профилактики рака печени
CN111072667A (zh) * 2018-10-22 2020-04-28 罗欣药业(上海)有限公司 五元或六元杂环并嘧啶类化合物及其用途
JP7695885B2 (ja) * 2019-02-12 2025-06-19 アンブルックス,インコーポレイテッド 抗体-tlrアゴニストコンジュゲートを含有する組成物、その方法、及び使用
JP7581336B2 (ja) 2019-09-20 2024-11-12 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 硫黄及びスルホキシミン含有置換基を有する殺有害生物的に活性な複素環式誘導体
US20230131192A1 (en) * 2020-01-27 2023-04-27 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
JP2023512204A (ja) * 2020-01-27 2023-03-24 ブリストル-マイヤーズ スクイブ カンパニー トール様受容体7(TLR7)アゴニストとしての1H-ピラゾロ[4,3-d]ピリミジン化合物
CN119604517A (zh) 2022-07-14 2025-03-11 豪夫迈·罗氏有限公司 用于治疗癌症的磷酰基嘌呤酮化合物
CN118724963A (zh) * 2023-03-30 2024-10-01 浙江养生堂天然药物研究所有限公司 含磷或含硫的大环化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4189048B2 (ja) * 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
EP1888587A1 (en) 2005-05-04 2008-02-20 Pfizer Limited 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c
CN101239980B (zh) 2008-02-18 2011-06-22 靳广毅 免疫受体调节剂偶联体前体和偶联体及其应用
ES2467108T3 (es) * 2008-12-09 2014-06-11 Gilead Sciences, Inc. Moduladores de receptores tipo toll
WO2011079016A1 (en) 2009-12-22 2011-06-30 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
TW201636330A (zh) * 2011-05-24 2016-10-16 拜耳知識產權公司 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺
RS57851B1 (sr) * 2011-11-09 2018-12-31 Janssen Sciences Ireland Uc Purinski derivati za tretman viralnih infekcija
AU2014242954B2 (en) 2013-03-29 2018-03-15 Janssen Sciences Ireland Uc Macrocyclic deaza-purinones for the treatment of viral infections
HUE054672T2 (hu) 2014-08-15 2021-09-28 Chia Tai Tianqing Pharmaceutical Group Co Ltd TLR7 agonistaként alkalmazott pirrolopirimidin vegyületek
PL3294740T3 (pl) * 2015-05-08 2020-03-31 F. Hoffmann-La Roche Ag Nowe sulfonoimidoilopurynony i pochodne do leczenia i profilaktyki infekcji wirusowych
AU2017320742B2 (en) * 2016-08-29 2021-08-05 F. Hoffmann-La Roche Ag 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection

Also Published As

Publication number Publication date
PT3294740T (pt) 2019-10-29
CN107580596B (zh) 2020-07-14
AR104528A1 (es) 2017-07-26
NZ775222A (en) 2024-09-27
JP6738352B2 (ja) 2020-08-12
HUE045906T2 (hu) 2020-01-28
LT3294740T (lt) 2019-11-25
AU2016260683B2 (en) 2020-10-29
TW201716410A (zh) 2017-05-16
NZ735648A (en) 2023-06-30
SG10202108841YA (en) 2021-09-29
KR20180003612A (ko) 2018-01-09
EP3294740B1 (en) 2019-09-04
US11242345B2 (en) 2022-02-08
US20200109144A1 (en) 2020-04-09
US20170275286A1 (en) 2017-09-28
KR102690131B1 (ko) 2024-07-31
MX2017014033A (es) 2018-03-01
CN107580596A (zh) 2018-01-12
HK1247925A1 (zh) 2018-10-05
CR20170496A (es) 2017-12-05
CA2982704A1 (en) 2016-11-17
RU2745269C2 (ru) 2021-03-22
MX2020010949A (es) 2022-06-16
ES2753777T3 (es) 2020-04-14
IL280769A (en) 2021-04-29
DK3294740T3 (da) 2019-11-04
MY182353A (en) 2021-01-20
MX393198B (es) 2025-03-19
TW202108584A (zh) 2021-03-01
AU2016260683A1 (en) 2017-10-12
RU2017142577A (ru) 2019-06-10
HRP20191942T1 (hr) 2020-01-10
MX376761B (es) 2025-03-07
IL254947A0 (en) 2017-12-31
RS59435B1 (sr) 2019-11-29
JP2018515509A (ja) 2018-06-14
IL280769B1 (en) 2023-03-01
US20160326177A1 (en) 2016-11-10
BR112017023959A2 (pt) 2018-07-17
TWI768467B (zh) 2022-06-21
PH12017502009A1 (en) 2018-03-26
EP3294740A1 (en) 2018-03-21
PL3294740T3 (pl) 2020-03-31
US9708325B2 (en) 2017-07-18
CA2982704C (en) 2023-10-24
CL2017002745A1 (es) 2018-05-18
SI3294740T1 (sl) 2019-12-31
TWI706954B (zh) 2020-10-11
RU2017142577A3 (https=) 2019-10-31
US10399983B2 (en) 2019-09-03
BR112017023959B1 (pt) 2023-05-02
AU2020256348B2 (en) 2022-06-16
IL280769B2 (en) 2023-07-01
AU2022204666A1 (en) 2022-07-21
IL254947B (en) 2021-02-28
WO2016180695A1 (en) 2016-11-17
CO2017009994A2 (es) 2018-02-20
PE20171620A1 (es) 2017-11-02
AU2020256348A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
UA120450C2 (uk) Сполуки і похідні сульфонімідоїлпуринону для лікування і профілактики вірусної інфекції
JP2023027102A (ja) オルトミクソウイルス感染症を治療するのに有用な縮合三環式ピリダジノン化合物
EP3983064B1 (en) Cot modulators and methods of use thereof
UA121532C2 (uk) Способи і проміжні сполуки при отриманні інгібітора jak
US20190144485A1 (en) Process for Making Chloro-substituted Nucleoside Phosphoramidate Compounds
TW202317550A (zh) 作為jak抑制劑之咪唑吲唑化合物
JP2024109855A (ja) ピロロ[2,3-d]ピリミジン誘導体
RU2819004C1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА
KR20230100919A (ko) 아미노피리미디닐 유도체
KR20230018459A (ko) 아미노피리미디닐 유도체
CN107406452B (zh) 吡唑并[3,4-d]嘧啶衍生物及其治疗利什曼病的用途
HK1247925B (zh) 用於治疗和预防病毒感染的新的磺亚氨酰基嘌呤酮化合物和衍生物